ERBB2 and breast carcinoma: This is in line with the data reported by Datta et al., which demonstrated that the treatment of breast cancer patients with HER‐2‐pulsed dendritic cells restore a depressed Th1 response mediated, for example, by IFN‐γ release.31, 45